Skip to main content
Scilex Holding Co logo

Scilex Holding Co — Investor Relations & Filings

Ticker · SCLX ISIN · US80880W2052 LEI · 529900SPEA2C7YTTYP45 US Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2022-09-14 Regulatory Filings
Country US United States of America
Listing US SCLX

About Scilex Holding Co

https://www.scilexholding.com/

Scilex Holding Co. is a company focused on the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company's portfolio targets indications with high unmet medical needs and features therapies with proprietary drug delivery systems. These systems include an advanced topical patch technology for optimized drug delivery through the skin, an anti-inflammatory oral solution designed for individualized dosing in high-risk patients, and a liquid ready-to-use analgesic for migraine relief. Scilex aims to provide effective alternatives to opioid medications to improve patient quality of life.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Vickers Vantage Corp. I. It details amendments to a merger agreement, a stockholder agreement, and a sponsor support agreement related to a merger transaction. The content focuses on merger-related agreements, amendments, and shareholder arrangements rather than financial results, earnings, or management changes. It is not an annual or quarterly report, audit report, earnings release, or management discussion. The document is a regulatory filing reporting material definitive agreements and amendments thereto, which is typical for Form 8-K filings. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-09-14 English
425 Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Vickers Vantage Corp. I. It details an amendment to a merger agreement, a stockholder agreement, and an amendment to a sponsor support agreement related to a merger transaction. The content focuses on merger-related agreements, amendments, and shareholder arrangements rather than financial results or management commentary. It is not an annual or quarterly report, earnings release, or audit report. It is also not a proxy solicitation or voting results announcement, but it references proxy materials filed elsewhere. The document is a regulatory filing reporting material definitive agreements and amendments related to a merger, which fits the category of Regulatory Filings (RNS) as it does not itself constitute a merger filing (like a DEFM14A) nor a full merger communication but is a current report on material events. Confidence is high given the clear SEC Form 8-K format and content.
2022-09-14 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter dated September 13, 2022, addressed to the SEC Division of Corporation Finance regarding Amendment No. 3 to a Registration Statement on Form S-4 filed by Vickers Vantage Corp. I. The content discusses responses to SEC comment letters, amendments to the Registration Statement, and details about the business combination, net tangible assets, dilution, and compliance with securities rules. The document is a correspondence letter responding to regulatory comments on a registration statement related to a merger or business combination transaction. It is not the registration statement itself, nor a proxy statement, nor a financial report. It is a regulatory filing correspondence letter responding to SEC comments, which fits best under Regulatory Filings (RNS). The document length (8064 characters) and content confirm it is not a brief announcement or a full report but a detailed regulatory correspondence.
2022-09-13 English
FORM S-4/A
M&A Activity Classification · 100% confidence The document is a Form S-4 Registration Statement filed with the SEC, which includes a proxy statement and prospectus related to an extraordinary general meeting (EGM) of shareholders. It discusses a business combination (merger) involving Vickers Vantage Corp. I and Scilex Holding Company, including details about the merger agreement, share exchanges, and shareholder voting. The presence of a proxy statement and notice of an extraordinary general meeting focused on approving a merger clearly indicates this is related to M&A activity. The document is not a full annual or quarterly report, audit report, or earnings release. It is not merely an announcement or a voting result but a detailed filing related to a merger transaction. Therefore, the appropriate classification is M&A Activity (TAR).
2022-09-13 English
425 Filing
Regulatory Filings Classification · 95% confidence The document is a press release announcing that the FDA has granted Fast Track Designation for a drug candidate (SP-103) by Scilex Holding Company, which is related to a proposed business combination with Vickers Vantage Corp. I. The text references regulatory filings such as a Registration Statement on Form S-4 and a proxy statement/prospectus related to the business combination. The document is primarily an announcement of a regulatory and corporate event, not a financial report, earnings release, or detailed management discussion. It does not contain financial statements or detailed financial analysis. It also does not fit into categories like M&A filings (MA) because it is not the merger filing itself but an announcement related to the transaction and regulatory status. The document is a regulatory announcement about the FDA designation and the upcoming shareholder vote materials. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2022-08-31 English
425 Filing
Regulatory Filings Classification · 95% confidence The document is a press release announcing an expansion of coverage for a pharmaceutical product and details about a proposed business combination between Scilex Holding Company and Vickers Vantage Corp. I. It references a definitive business combination agreement and mentions that a proxy statement/prospectus will be filed with the SEC and sent to shareholders for voting on the proposed transaction. The document is not a full financial report, audit, or earnings release, nor is it a direct proxy solicitation document itself. Instead, it is an announcement related to the upcoming proxy materials and the business combination transaction. The document is about the announcement of the transaction and related shareholder meeting materials, not the materials themselves. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement and does not fit more specific categories like Proxy Solicitation & Information Statement (PSI) or Merger & Acquisition (MA) filings which would be the actual proxy or merger documents.
2022-08-16 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.